EBRGD / Molecular Targeting Tech, National Institutes of Health - LARVOL DELTA

MTTI Awarded $3.17 Million NCI Grant to Advance ¹⁷⁷Lu-EBRGD Development for Non-Small Cell Lung Cancer (Businesswire) - "The award, under NIH grant R01CA299133, will support an integrated translational program encompassing preclinical research, drug product manufacturing, regulatory preparation, and planned clinical studies. These activities are intended to establish the scientific, manufacturing, and regulatory foundation for evaluating ¹⁷⁷Lu-EBRGD in patients with NSCLC, subject to applicable regulatory requirements and clinical readiness."

Financing • Non Small Cell Lung Cancer